Please assess the completion status of the following clinical trial:

Trial Title: Survey of Inhibitors in Plasma-Product Exposed Toddlers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects~* Any ethnicity~* Age \<6 years~* Severe haemophilia A (FVIII:C \<1%), as confirmed at enrolment by the central laboratory.~  o Those patients diagnosed locally as severe but subsequently found to have FVIII levels \>= 1% on testing at the central laboratory will be separately recorded in the screening list.~* Previously untreated (0 EDs to any FVIII concentrates or blood products) or minimally treated (\<5 EDs) with blood components, namely whole blood, fresh frozen plasma, packed red blood cells, platelets or cryoprecipitate.~  o Patients not meeting these criteria will be separately recorded in the screening list.~* Negative inhibitor measurement at both local and central laboratory at screening~* Ability to comply with study requirements~* Signed informed consent of legal tutors o Patients who will not accept to enter into the study or to be randomized will be separately recorded.~Exclusion Criteria:~* Previous history of FVIII inhibitor~* Other congenital or acquired bleeding defects~* Plasma FVIII level \>= 1%, as assayed at the central laboratory~  o Those patients originally diagnosed locally as severe but subsequently found to have FVIII levels ranging from 1% to 2% on testing at the central laboratory will be separately recorded in the screening list.~* Concomitant congenital or acquired immunodeficiency~* Concomitant treatment with systemic immunosuppressive drugs~* Concomitant treatment with any investigational drug

- Gender: MALE
- Minimum Age: 1 Minute
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- PLASMA DERIVED Factor VIII (Type: ACTIVE_COMPARATOR): Plasma-derived vWF/FVIII
- rFVIII (Type: ACTIVE_COMPARATOR): Recombinant FVIII

Based on this trial design, predict the completion outcome and termination type (if applicable).